Literature DB >> 3426305

Treatment of Raynaud's phenomenon with large doses of triiodothyronine: a pilot study.

P H Dessein, R F Gledhill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3426305      PMCID： PMC1003429          DOI： 10.1136/ard.46.12.944

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Plasma exchange and platelet function in Raynaud's phenomenon.

Authors:  J Zahavi; W A Hamilton; M J O'Reilly; J Leyton; L T Cotton; V V Kakkar
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

2.  Local regulation of digital blood flow in generalized scleroderma.

Authors:  J K Kristensen
Journal:  J Invest Dermatol       Date:  1979-05       Impact factor: 8.551

3.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

4.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16
  4 in total
  3 in total

1.  Pulmonary hypertension in Sjögren's syndrome.

Authors:  R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

2.  Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism.

Authors:  A M Lateiwish; J Fehér; K Baraczka; K Rácz; R Kiss; E Gláz
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

3.  Treatment of Raynaud's phenomenon with triiodothyronine corrects co-existent autonomic dysfunction: preliminary findings.

Authors:  R F Gledhill; P H Dessein; C A Van der Merwe
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.